Genexine (XKRX:095700) Common Stock : ₩20,755 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Common Stock?

Genexine's quarterly common stock stayed the same from Sep. 2023 (₩20,755 Mil) to Dec. 2023 (₩20,755 Mil) and stayed the same from Dec. 2023 (₩20,755 Mil) to Mar. 2024 (₩20,755 Mil).

Genexine's annual common stock increased from Dec. 2021 (₩12,515 Mil) to Dec. 2022 (₩12,572 Mil) and increased from Dec. 2022 (₩12,572 Mil) to Dec. 2023 (₩20,755 Mil).

Genexine Common Stock Historical Data

The historical data trend for Genexine's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Common Stock Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

11,880.65

12,348.89

12,514.57

12,572.49

20,755.30

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															20,158.38	20,755.30	20,755.30	20,755.30	20,755.30

Genexine Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines